Tirzepatide — GLP-1/GIP twincretin agonist
In short
Dual agonist of GLP-1 and GIP receptors studied in clinical models for synergistic control of metabolism and body weight.
Overview
Tirzepatide combines GIP and receptor agonism in a single 39-amino-acid molecule with a 20-carbon fatty acid moiety for albumin binding (~5-day half-life). The dual mechanism activates both incretin axes simultaneously — a strategy validated by SURPASS (T2D) and SURMOUNT (obesity) Phase 3 programs. SURMOUNT-1 (NEJM 2022) reported 22.5% mean weight loss at 15 mg/week, the largest effect size yet documented for pharmacological weight reduction.
Tirzepatide is a balanced co-agonist at GIP-R and GLP-1R. GIP activation enhances first-phase insulin response and lipid handling; activation provides appetite suppression, gastric-emptying delay, and glucagon suppression. The synergy yields superior weight and glycemic outcomes versus selective agonists, though the mechanism of the additive effect remains under investigation.
Molecular information
First-order decay curve at 120.0h half-life from literature. Educational only.
Профилът на нежелани събития прилича на моноагонистите със сходно гастроинтестинално преобладаване. Гадене, повръщане, диария и запек са най-чести по време на титрация. Острият панкреатит е class-effect сигнал. Двойният механизъм не изглежда да добавя нови сигнали за безопасност извън класа към момента, въпреки че дългосрочни сърдечно-съдови данни все още се натрупват (SURPASS-CVOT в ход).
5 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Information about Tirzepatide is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.
